Roche has received US Food and Drug Administration approval for a new pharmacogenetic indication for the non-small cell lung cancer drug Tarceva (erlotinib) and a companion test that picks out best responders to the treatment.

The agency announced this week that it had approved Roche's Cobas EGFR Mutation test as a companion diagnostic for Tarceva when it is given as a first-line treatment for metastatic NSCLC patients whose tumors harbor certain EGFR mutations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.